Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience

Toru Ikegami; Yoshihide Ueda; Nobuhisa Akamatsu; Kohei Ishiyama; Ryoichi Goto; Akihiko Soyama; Kaori Kuramitsu; Masaki Honda; Masahiro Shinoda; Tomoharu Yoshizumi; Hideaki Okajima; Yuko Kitagawa; Yukihiro Inomata; Yonson Ku; Susumu Eguchi; Akinobu Taketomi; Hideki Ohdan; Norihiro Kokudo; Mitsuo Shimada; Katsuhiko Yanaga; Hiroyuki Furukawa; Shinji Uemoto; Yoshihiko Maehara

doi:10.1111/ctr.13109

Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience

Toru Ikegami, Yoshihide Ueda, Nobuhisa Akamatsu, Kohei Ishiyama, Ryoichi Goto, Akihiko Soyama, Kaori Kuramitsu, Masaki Honda, Masahiro Shinoda, Tomoharu Yoshizumi, Hideaki Okajima, Yuko Kitagawa, Yukihiro Inomata, Yonson Ku, Susumu Eguchi, Akinobu Taketomi, Hideki Ohdan, Norihiro Kokudo, Mitsuo Shimada, Katsuhiko YanagaHiroyuki Furukawa, Shinji Uemoto, Yoshihiko Maehara

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

The safety and efficacy of an IFN-free regimen using asunaprevir (ASV) and daclatasvir (DCV) for recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) have not been evaluated in Japan. A multicenter study of LT recipients (n = 74) with recurrent HCV genotype 1b infection treated with ASV-DCV for 24 weeks was performed. Medical history was positive for pegylated interferon and ribavirin (Peg-IFN/RBV) in 40 (54.1%) patients, and for simeprevir (SMV) with Peg-IFN/RBV in 12 (16.2%) patients. Resistance-associated variants (RAVs) were positive at D168 (n = 1) in the NS3, and at L31 (n = 4), Y93 (n = 4), and L31/Y93 (n = 1) in the NS5A region of the HCV genome. Sixty-one (82.4%) patients completed the 24-week treatment protocol. Although sustained viral response (SVR) was achieved in 49 (80.3%) patients, it was achieved in only two (16.7%) patients among those with histories of receiving SMV (n = 12). Univariate analysis showed that a history of SMV (P <.01) and the presence of mutations in NS5A (P =.02) were the significant factors for no-SVR. By excluding the patients with either a history of SMV-based treatment or RAVs in NS3/NS5A, the SVR rate was 96.4%. By excluding the patients with a history of SMV and those with RAVs in NS3/NS5A, viral clearance of ASV-DCV was favorable, with a high SVR rate.

Original language	English
Article number	e13109
Journal	Clinical Transplantation
Volume	31
Issue number	11
DOIs	https://doi.org/10.1111/ctr.13109
Publication status	Published - 2017 Nov

Keywords

asunaprevir
daclatasvir
hepatitis C
liver transplantation

ASJC Scopus subject areas

Transplantation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/ctr.13109

Cite this

Ikegami, T., Ueda, Y., Akamatsu, N., Ishiyama, K., Goto, R., Soyama, A., Kuramitsu, K., Honda, M., Shinoda, M., Yoshizumi, T., Okajima, H., Kitagawa, Y., Inomata, Y., Ku, Y., Eguchi, S., Taketomi, A., Ohdan, H., Kokudo, N., Shimada, M., ... Maehara, Y. (2017). Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience. Clinical Transplantation, 31(11), [e13109]. https://doi.org/10.1111/ctr.13109

Ikegami, T, Ueda, Y, Akamatsu, N, Ishiyama, K, Goto, R, Soyama, A, Kuramitsu, K, Honda, M, Shinoda, M, Yoshizumi, T, Okajima, H, Kitagawa, Y, Inomata, Y, Ku, Y, Eguchi, S, Taketomi, A, Ohdan, H, Kokudo, N, Shimada, M, Yanaga, K, Furukawa, H, Uemoto, S & Maehara, Y 2017, 'Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience', Clinical Transplantation, vol. 31, no. 11, e13109. https://doi.org/10.1111/ctr.13109

@article{8a86cc6223a24a4f99c480a121278fd4,

title = "Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience",

abstract = "The safety and efficacy of an IFN-free regimen using asunaprevir (ASV) and daclatasvir (DCV) for recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) have not been evaluated in Japan. A multicenter study of LT recipients (n = 74) with recurrent HCV genotype 1b infection treated with ASV-DCV for 24 weeks was performed. Medical history was positive for pegylated interferon and ribavirin (Peg-IFN/RBV) in 40 (54.1%) patients, and for simeprevir (SMV) with Peg-IFN/RBV in 12 (16.2%) patients. Resistance-associated variants (RAVs) were positive at D168 (n = 1) in the NS3, and at L31 (n = 4), Y93 (n = 4), and L31/Y93 (n = 1) in the NS5A region of the HCV genome. Sixty-one (82.4%) patients completed the 24-week treatment protocol. Although sustained viral response (SVR) was achieved in 49 (80.3%) patients, it was achieved in only two (16.7%) patients among those with histories of receiving SMV (n = 12). Univariate analysis showed that a history of SMV (P <.01) and the presence of mutations in NS5A (P =.02) were the significant factors for no-SVR. By excluding the patients with either a history of SMV-based treatment or RAVs in NS3/NS5A, the SVR rate was 96.4%. By excluding the patients with a history of SMV and those with RAVs in NS3/NS5A, viral clearance of ASV-DCV was favorable, with a high SVR rate.",

keywords = "asunaprevir, daclatasvir, hepatitis C, liver transplantation",

author = "Toru Ikegami and Yoshihide Ueda and Nobuhisa Akamatsu and Kohei Ishiyama and Ryoichi Goto and Akihiko Soyama and Kaori Kuramitsu and Masaki Honda and Masahiro Shinoda and Tomoharu Yoshizumi and Hideaki Okajima and Yuko Kitagawa and Yukihiro Inomata and Yonson Ku and Susumu Eguchi and Akinobu Taketomi and Hideki Ohdan and Norihiro Kokudo and Mitsuo Shimada and Katsuhiko Yanaga and Hiroyuki Furukawa and Shinji Uemoto and Yoshihiko Maehara",

note = "Funding Information: This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Health, Labour and Welfare, Japan (17fk0210107 h0001). Publisher Copyright: {\textcopyright} 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd",

year = "2017",

month = nov,

doi = "10.1111/ctr.13109",

language = "English",

volume = "31",

journal = "Clinical Transplantation",

issn = "0902-0063",

publisher = "Wiley-Blackwell",

number = "11",

}

TY - JOUR

T1 - Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation

T2 - A Japanese multicenter experience

AU - Ikegami, Toru

AU - Ueda, Yoshihide

AU - Akamatsu, Nobuhisa

AU - Ishiyama, Kohei

AU - Goto, Ryoichi

AU - Soyama, Akihiko

AU - Kuramitsu, Kaori

AU - Honda, Masaki

AU - Shinoda, Masahiro

AU - Yoshizumi, Tomoharu

AU - Okajima, Hideaki

AU - Kitagawa, Yuko

AU - Inomata, Yukihiro

AU - Ku, Yonson

AU - Eguchi, Susumu

AU - Taketomi, Akinobu

AU - Ohdan, Hideki

AU - Kokudo, Norihiro

AU - Shimada, Mitsuo

AU - Yanaga, Katsuhiko

AU - Furukawa, Hiroyuki

AU - Uemoto, Shinji

AU - Maehara, Yoshihiko

N1 - Funding Information: This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Health, Labour and Welfare, Japan (17fk0210107 h0001). Publisher Copyright: © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

PY - 2017/11

Y1 - 2017/11

N2 - The safety and efficacy of an IFN-free regimen using asunaprevir (ASV) and daclatasvir (DCV) for recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) have not been evaluated in Japan. A multicenter study of LT recipients (n = 74) with recurrent HCV genotype 1b infection treated with ASV-DCV for 24 weeks was performed. Medical history was positive for pegylated interferon and ribavirin (Peg-IFN/RBV) in 40 (54.1%) patients, and for simeprevir (SMV) with Peg-IFN/RBV in 12 (16.2%) patients. Resistance-associated variants (RAVs) were positive at D168 (n = 1) in the NS3, and at L31 (n = 4), Y93 (n = 4), and L31/Y93 (n = 1) in the NS5A region of the HCV genome. Sixty-one (82.4%) patients completed the 24-week treatment protocol. Although sustained viral response (SVR) was achieved in 49 (80.3%) patients, it was achieved in only two (16.7%) patients among those with histories of receiving SMV (n = 12). Univariate analysis showed that a history of SMV (P <.01) and the presence of mutations in NS5A (P =.02) were the significant factors for no-SVR. By excluding the patients with either a history of SMV-based treatment or RAVs in NS3/NS5A, the SVR rate was 96.4%. By excluding the patients with a history of SMV and those with RAVs in NS3/NS5A, viral clearance of ASV-DCV was favorable, with a high SVR rate.

AB - The safety and efficacy of an IFN-free regimen using asunaprevir (ASV) and daclatasvir (DCV) for recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) have not been evaluated in Japan. A multicenter study of LT recipients (n = 74) with recurrent HCV genotype 1b infection treated with ASV-DCV for 24 weeks was performed. Medical history was positive for pegylated interferon and ribavirin (Peg-IFN/RBV) in 40 (54.1%) patients, and for simeprevir (SMV) with Peg-IFN/RBV in 12 (16.2%) patients. Resistance-associated variants (RAVs) were positive at D168 (n = 1) in the NS3, and at L31 (n = 4), Y93 (n = 4), and L31/Y93 (n = 1) in the NS5A region of the HCV genome. Sixty-one (82.4%) patients completed the 24-week treatment protocol. Although sustained viral response (SVR) was achieved in 49 (80.3%) patients, it was achieved in only two (16.7%) patients among those with histories of receiving SMV (n = 12). Univariate analysis showed that a history of SMV (P <.01) and the presence of mutations in NS5A (P =.02) were the significant factors for no-SVR. By excluding the patients with either a history of SMV-based treatment or RAVs in NS3/NS5A, the SVR rate was 96.4%. By excluding the patients with a history of SMV and those with RAVs in NS3/NS5A, viral clearance of ASV-DCV was favorable, with a high SVR rate.

KW - asunaprevir

KW - daclatasvir

KW - hepatitis C

KW - liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=85030242819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030242819&partnerID=8YFLogxK

U2 - 10.1111/ctr.13109

DO - 10.1111/ctr.13109

M3 - Article

C2 - 28881052

AN - SCOPUS:85030242819

SN - 0902-0063

VL - 31

JO - Clinical Transplantation

JF - Clinical Transplantation

IS - 11

M1 - e13109

ER -

Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this